A congressional committee has asked the chief executive officer of Purdue Pharma and some members of the Sackler family that controls the company to testify at a hearing next month that will explore the role the drug maker played in fueling the opioid crisis in the U.S.
In a series of letters issued Wednesday, the House Committee on Oversight and Reform cited internal documents it released last month that helped to reinforce previous impressions — gleaned from years of litigation — about the way the drug maker was run by the secretive clan. The Dec. 8 hearing is an outgrowth of its investigation.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
